Want to see BRNS full AI Analyst Report?
Top Page
Barinthus Biotherapeutics
(NASDAQ:BRNS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.54
▼(-10.00% Downside)
Action:Reiterated
Date:07/03/26
The score is held down primarily by weak financial performance (volatile/episodic revenue, widening losses, and persistent cash burn) and bearish technical signals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend, while corporate events are mixed—offsetting positives (transaction progress, CFO hire) against meaningful listing-compliance risk.
Positive Factors
Low leverage
Consistently low debt levels provide durable financial flexibility for a clinical-stage biotech. With modest leverage, the company can prioritize R&D financing, negotiate partnerships, or raise equity without immediate debt-servicing pressure, reducing near-term solvency risk.
Negative Factors
Persistent negative cash flow
Chronic negative operating and free cash flow indicate the business consumes cash to sustain operations and trials. This structural cash burn requires repeated external funding, increasing dilution risk and potentially limiting ability to advance programs without partner deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Consistently low debt levels provide durable financial flexibility for a clinical-stage biotech. With modest leverage, the company can prioritize R&D financing, negotiate partnerships, or raise equity without immediate debt-servicing pressure, reducing near-term solvency risk.
Read all positive factors
Barinthus Biotherapeutics (BRNS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.79M
Dividend YieldN/A
Average Volume (3M)124.73K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue Growth-100.00%
EPS Growth21.30%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.29
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.15
Revenue Forecast (FY)N/A
Barinthus Biotherapeutics Business Overview & Revenue Model
Company Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chroni...
How the Company Makes Money
null...
Barinthus Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 14.97M | 802.00K | 44.70M | 268.00K |
| Gross Profit | -1.76M | -5.86M | 14.97M | 802.00K | 44.70M | 268.00K |
| EBITDA | -47.73M | -62.90M | -55.37M | -71.06M | 5.19M | -47.87M |
| Net Income | -52.29M | -66.58M | -61.07M | -73.35M | 5.34M | -50.87M |
Balance Sheet | ||||||
| Total Assets | 92.14M | 98.17M | 160.33M | 214.51M | 270.20M | 280.71M |
| Cash, Cash Equivalents and Short-Term Investments | 67.19M | 70.46M | 110.66M | 142.09M | 194.38M | 214.05M |
| Total Debt | 11.01M | 11.28M | 12.01M | 12.98M | 8.77M | 7.22M |
| Total Liabilities | 25.66M | 23.88M | 30.19M | 27.51M | 27.00M | 28.15M |
| Stockholders Equity | 66.40M | 74.21M | 130.03M | 186.78M | 242.90M | 252.13M |
Cash Flow | ||||||
| Free Cash Flow | -36.48M | -48.02M | -29.83M | -56.34M | -20.57M | -33.73M |
| Operating Cash Flow | -36.44M | -47.98M | -28.94M | -50.92M | -14.43M | -32.58M |
| Investing Cash Flow | 476.00K | 416.00K | -892.00K | -5.41M | -5.75M | -12.91M |
| Financing Cash Flow | 0.00 | 2.00K | 2.16M | 1.87M | 325.00K | 222.74M |
Barinthus Biotherapeutics Risk Analysis
Barinthus Biotherapeutics disclosed 109 risk factors in its most recent earnings report. Barinthus Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Barinthus Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $261.05M | -1.18 | -124.06% | ― | ― | 39.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $26.18M | -0.49 | -139.47% | ― | 43.88% | 14.79% | |
44 Neutral | $22.79M | -0.43 | -63.87% | ― | -100.00% | 21.30% | |
44 Neutral | $11.01M | -2.95 | -70.74% | ― | 373.88% | -59.79% | |
44 Neutral | $56.19M | -1.00 | -53.60% | ― | ― | 15.42% | |
40 Underperform | $5.16M | -0.26 | -160.28% | ― | -84.26% | 14.73% |
* Healthcare Sector Average
BRNS
Barinthus Biotherapeutics
0.56
-0.82
-59.13%
CLGN
Collplant Holdings
0.29
-1.96
-87.29%
ALXO
ALX Oncology Holdings
1.97
1.31
198.48%
ALGS
Aligos Therapeutics
4.75
-3.16
-39.95%
GDTC
CytoMed Therapeutics Limited
0.85
-0.95
-52.67%
BOLD
Boundless Bio Inc.
2.71
1.53
129.24%
Barinthus Biotherapeutics Corporate Events
Executive/Board ChangesDelistings and Listing ChangesDividendsRegulatory Filings and ComplianceShareholder Meetings
Barinthus Biotherapeutics Holds 2026 Annual General Meeting
Negative
Jul 2, 2026
Barinthus Biotherapeutics held its 2026 Annual General Meeting on July 2, 2026, where shareholders approved all resolutions, including the re-election of directors Karen T. Dawes and Anne M. Phillips and the reappointment and remuneration authoriz...
Business Operations and StrategyM&A TransactionsShareholder Meetings
Barinthus Biotherapeutics Shareholders Approve Scheme of Arrangement
Positive
May 21, 2026
On May 20, 2026, Barinthus Biotherapeutics shareholders and scheme shareholders overwhelmingly approved a court-sanctioned Scheme of Arrangement and related implementation resolutions at separate court and general meetings. The votes, representing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.